Related Experiment Video
Updated: Jun 4, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene
B Muehlenweg1, A Schnelzer, B Türkmen
1Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany.
Methods in Molecular Medicine
|February 23, 2011
Summary
High levels of urokinase-type plasminogen activator (uPA) indicate a poor prognosis in solid tumors. This enzyme is crucial for tumor invasiveness by degrading the extracellular matrix and influencing cell attachments.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Tumor invasiveness is linked to proteolytic enzymes that degrade the extracellular matrix.
- Urokinase-type plasminogen activator (uPA) is a key serine protease in pericellular proteolysis.
- uPA converts plasminogen to plasmin, degrading matrix components and activating metalloproteases.
Purpose of the Study:
- To investigate the role of uPA and its associated factors in tumor progression.
- To establish uPA as a prognostic marker for solid malignant tumors.
Main Methods:
- Analysis of uPA expression and activity in tumor samples.
- Correlation of uPA levels with patient prognosis and survival rates.
- Evaluation of the uPA system, including uPAR and PAI-1.
Main Results:
- High levels of uPA are consistently associated with a poor prognosis in various solid tumors.
- Elevated uPA correlates with reduced relapse-free and overall survival.
- The uPA system, including uPAR and PAI-1, serves as an important prognostic factor.
Conclusions:
- uPA is a critical mediator of tumor cell invasion and extracellular matrix degradation.
- uPA and its related factors are significant biomarkers for predicting outcomes in cancer patients.
- Targeting the uPA system may offer therapeutic strategies for improving cancer prognosis.
